Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Status:
Recruiting
Trial end date:
2023-05-12
Target enrollment:
Participant gender:
Summary
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the
treatment of metastatic differentiated thyroid cancer. Patients will be treated with
Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19.
Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo
imaging to evaluate efficacy once every 2 cycles.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center